Abstract
This Insight Pharma Report focuses on the applications, technology and market
aspects of high-content analysis (HCA) - a field that originated when
automated microscopic imaging technology joined with the high-throughput
screening paradigm that signified the birth of “industrialized drug
discovery”.
This report discusses:
- Development of the HCA field from the commercial, scientific, and
technological perspectives
- Technologies that underlie HCA and the full range of systems that are
available today
- Applications of HCA in areas including cell signaling, cell and organism
physiology, toxicology, target validation, and drug discovery
- Market dynamics, including a competitive analysis and an examination of
recent HCA deals
- Results from an Insight Pharma Reports online survey of people who are
active in the HCA field
- Interviews with individuals who are highly knowledgeable in the HCA field,
which were conducted exclusively for this report
High-throughput screening (HTS), used for the en masse discovery of compounds
that interact with molecular drug targets, provides many more hits than viable
drug candidates. In the last decade, HCS (high-content screening), based
largely on automated imaging technology, has come to provide a form of
secondary screening in which hits can be tested efficiently for their effects
on cells. Applications of HCS have diversified into what is now called HCA
(high-content analysis), a more generalized term that covers areas such as
target identification, pathway analysis, mechanism of action verification, and
cell biology research in general.
High-Content Analysis: Technologies, Applications, and Market Dynamics begins
by examining the evolution and nature of HCA. The several variant definitions
of HCA/HCS that have been offered are addressed, before turning to an
examination of the technological aspects of HCA. In addition to automated
microscopic imaging systems, also covered are flow cytometry from the HCA
perspective, live cell and kinetic HCA, the role of primary cells and stem
cells, and the nature of informatics systems supporting HCA investigations.
This report next addresses HCA applications in areas that include cell
signaling, cell and organism physiology, toxicology, and target identification
and validation before turning specifically to applications in drug discovery,
including primary and secondary screening. Other topics covered are the role
of service organizations, the nature and sources of cells and other sample
types, and applications in cell biology research.
High-Content Analysis: Technologies, Applications, and Market Dynamics then
turns to an analysis of market dynamics in terms of the competitive landscape
among vendors, deals and deal patterns, and results from a survey of
individuals who use HCA. We conclude by summarizing our findings, discussing
possible future directions in the HCA field, and addressing the key questions:
- Why are so many large companies interested in HCA?
- What do HCA systems manufacturers need to do to keep the market growing at
a healthy clip?
- Is HCA making a significant impact on drug discovery?
About the Author
Ken Rubenstein, PhD, a biochemist and molecular biologist, received his
PhD at the University of Wisconsin and postdoctoral training at the University
Of Pennsylvania School Of Medicine. He was a key innovator and research
manager for Syva Company, the diagnostics branch of Syntex Corporation. During
his 13 years with Syva, Dr. Rubenstein became vice president, scientific
affairs, and a function that included strategic planning. Since 1983, he has
served as a technology and marketing consultant to biomedical companies and an
industry analyst, with more than 40 published studies to his credit.
Table of Contents
Executive Summary
- Evolution of the Field and Definitions
- Technological Aspects of HCA
- HCA Applications
- Market Dynamics
- Observations and Trends
Chapter - 1
- Introduction
- Scope and Format of the Report
Chapter - 2
- Evolution and Nature of HCA
- HTS Gives Rise to HCS
- The Rise of HCS Systems: A Prelude to HCA
- HCA/HCS Definitions
Chapter - 3
- Technological Aspects of HCA
- 3.1. HCA Platforms
- 3.2. Flow Cytometry
- 3.3. Live Cell HCA
- 3.4. Primary and Stem Cells
- 3.5. Informatics
- Third-Party Software
- Open-Source Software
Chapter - 4
- HCA Applications
- 4.1. Cell Signaling
- 4.2. Cell and Organism Physiology
- 4.3. Toxicology
- 4.4. Target Identification and Validation
- 4.5. Applications of HCS in Drug Discovery
- Primary HCS Testing
- Secondary HCS
- Service Organizations
- 4.6. Nature and Sources of Cells and Other Sample Types
- Cells
- Tissues and Surrogates
- Organisms
- 4.7. Applications of HCS in Basic Cell Biology Research and
Academic Screening Centers
Chapter - 5
- Market Dynamics
- 5.1. Competitive Landscape
- 5.2. Deals
- 5.3. User Survey
- Title
- Activity
- Type of Organization
- Application Usage Frequency
- Disease Categories
- Instrument Access
- Instrument Type
- Instrument Location
- Frequency of Employing Sample Types and Assay Modalities
- Reagent Sourcing Frequency
- Importance of Instrument Parameters and Attributes
Chapter - 6
- Observations and Trends
- 6.1. Large Company Interest in HCA
- 6.2. Requirements for Future Market Growth
- 6.3. HCA's Impact on Drug Discovery
- 6.4. Conclusion
Chapter - 7
- Expert Interview Transcripts
- 7.1. Joseph Zock, IntelliCyt Corporation, Senior Director Product
Management
- 7.2. Mark Collins, PhD, Director of Global Marketing for Life
Science Research, Cellomics
- 7.3. William Busa, PhD, President, Busa Consulting
- 7.4. Leo Bleicher, Product Manager, Imaging Component Collection,
Accelrys
- 7.5. Michelle Palmer, PhD, Director of Discovery and Preclinical
Research, Broad Institute
- 7.6. Evan Cromwell, PhD, Director of Research, Molecular Devices
References
Company Index
TABLES
- Table 3.1. Identity and attributes of some HCA systems
- Table 3.2. Software Provided by Systems Manufacturers
- Table 3.3. Open-Source Software for HCA/HCS
- Table 5.1. Selected recent HCS/HCA deals
- Table 5.2. Frequency (%) with which respondents are involved with
particular applications
- Table 5.3. Frequency (%) with which respondent employs indicated sample
type or assay modality
- Table 5.4. Frequency (%) with which respondent plans to employ indicated
sample type or assay modality in the next two years
- Table 5.5. Frequency (%) with which respondents use three sources of
reagents
- Table 5.6. Importance of instrument parameters/attributes
FIGURES
- Figure 3.1. Diagram of confocal principle
- Figure 3.2. BD Biosciences 855, schematic of the light path
- Figure 3.3. The CompuCyte iCys LSC system in schematic
- Figure 5.1. Respondents' position in the HCS/HCA field
- Figure 5.2. Nature of respondents' work in the HCS/HCA field
- Figure 5.3. Nature of respondents' organization
- Figure 5.4. Respondents' disease categories
- Figure 5.5. Number of HCS/HCA instruments onsite in organization
- Figure 5.6. Number of HCS/HCA instruments respondent has access to
- Figure 5.7. Dominant instrument type to which respondent has access for
HCS/HCA
- Figure 5.8. Location of instruments to which respondent has access
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
